Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, not just today’s reading.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Harmony Biosciences stock (HRMY) sits at $39.92, up 0.71% today. The business is worth $2.32B in the market, good for #2678 of 3132 on our coverage list.
The 52-week range is $25.52 to $43.49. Today's price is about 80% of the way from the low to the high. Holders are ahead 50.1% over twelve months, and up 4.3% across the last three months.
On the chart it holds above both the 50-day ($39.63) and 200-day ($34.65) moving averages; RSI is 47, and the last 30 sessions moved at roughly 27% annualized volatility.
Buyers are paying 12.9 times trailing earnings, 34% below its five-year average of 19.6. The median for its industry group is 21.2.
7 analysts follow the stock and the average call is "buy". The mean target, $46.43, sits 16.3% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 3 factors below, ranked against the 3132 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Trading closer to its 52-week high than most peers scores higher.
7 analysts, consensus Buy.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
HRMY is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $46.43, 16.3% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $48.60, so shares trade 17.9% below that estimate. On earnings multiple, it sits in the 41st percentile of its own five-year valuation range (cheaper than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | -2.8% | Bearish |
| Price vs 50-day average | +0.7% | Bullish |
| Price vs 200-day average | +15.2% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 46.8 | Bearish |
| MACD (12,26,9) | -0.07 | Bearish |
| Bollinger band position | 24% | Bearish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 5, 2026 10:20 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,132 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 12.9x earnings, HRMY looks cheap against the market, and trades 39% below the 21.2x median among Biotechnology names. The two comparisons do not always agree.
$39.92 is the latest print for HRMY, a move of +0.71% against yesterday's close of $39.64. Today's low and high so far: $39.51 and $40.77.
Equity value comes to $2.32B at the current price. By that measure it is number 2678 of the 3132 names in our coverage.
Buyers pay 12.9 times the last twelve months of profit (EPS $2.71). Averaged over five years the multiple has been 19.6, and today's level ranks in the 41st percentile of its own history.
The year's floor is $25.52 and the ceiling $43.49. Shares are 8.2% away from that ceiling.
Our data shows no dividend paid by Harmony Biosciences over the trailing twelve months.
Of 7 analysts, 57% say buy, 29% hold and 14% sell. Price targets average $46.43, with the most cautious at $30.00 and the most optimistic at $60.00.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on HRMY.